1)Hjorthøj C, Stürup AE, McGrath JJ, et al:Years of potential life lost and life expectancy in schizophrenia:A systematic review and meta-analysis. Lancet Psychiatry 4:295-301, 2017[PMID:28237639]
2)Olfson M, Gerhard T, Huang C, et al:Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry 72:1172-1181, 2015[PMID:26509694]
3)Mitchell AJ, Vancampfort D, Sweers K, et al:Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis. Schizophr Bull 39:306-318, 2013[PMID:22207632]
4)Hagi K, Nosaka T, Dickinson D, et al:Association between cardiovascular risk factors and cognitive impairment in people with schizophrenia:A systematic review and meta-analysis. JAMA Psychiatry 78:510-518, 2021[PMID:33656533]
5)Hanley AJ, Karter AJ, Williams K, et al:Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome:The insulin resistance atherosclerosis study. Circulation 112:3713-3721, 2005[PMID:16344402]
6)Gami AS, Witt BJ, Howard DE, et al:Metabolic syndrome and risk of incident cardiovascular events and death:A systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 49:403-414, 2007[PMID:17258085]
7)Sugai T, Suzuki Y, Yamazaki M, et al:Difference in prevalence of metabolic syndrome between Japanese outpatients and inpatients with schizophrenia:A nationwide survey. Schizophr Res 171:68-73, 2016[PMID:26811231]
8)Mitchell AJ, Vancampfort D, Herdt AD, et al:Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr Bull 39:295-305, 2013[PMID:22927670]
9)Wu H, Siafis S, Hamza T, et al:Antipsychotic-induced weight gain:Dose-response meta-analysis of randomized controlled trials. Schizophr Bull 48:643-654, 2022[PMID:35137229]
10)Sawagashira R, Yamamura R, Okubo R, et al:Subthreshold change in glycated hemoglobin and body mass index after the initiation of second-generation antipsychotics among patients with schizophrenia or bipolar disorder:A nationwide prospective cohort study in Japan. J Clin Psychiatry 83:21m14099, 2022[PMID:35377566]
11)久住一郎:統合失調症における糖脂質代謝障害の発症リスクに対する生物学的脆弱性と抗精神病薬治療の影響.臨床精神薬理 25:383-389, 2022
12)American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity:Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596-601, 2004[PMID:14747245]
13)Mitchell AJ, Delaffon V, Vancampfort D, et al:Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication:Systematic review and meta-analysis of screening practices. Psychol Med 42:125-147, 2012[PMID:21846426]
14)Mukundan A, Faulkner G, Cohn T, et al:Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev:CD006629, 2010[PMID:21154372]
15)Caemmerer J, Correll CU, Maayan L:Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities:A meta-analytic comparison of randomized controlled trials. Schizophr Res 140:159-168, 2012[PMID:22763424]
16)Sugawara N, Sagae T, Yasui-Furukori N, et al:Effects of nutritional education on weight change and metabolic abnormalities among patients with schizophrenia in Japan:A randomized controlled trial. J Psychiatr Res 97:77-83, 2018[PMID:29220825]
17)Jauhar S, Johnstone M, McKenna PJ:Schizophrenia. Lancet 399:473-486, 2022[PMID:35093231]
18)Bora E, Akdede BB, Alptekin K:The relationship between cognitive impairment in schizophrenia and metabolic syndrome:A systematic review and meta-analysis. Psychol Med 47:1030-1040, 2017[PMID:28032535]